Abstract. Lung cancer is the leading cause of cancer-associated mortality. Tumor-associated neutrophils represent a large portion of inflammatory cells within the lung tumor microenvironment. However, the roles of neutrophil extracellular traps (NETs) in lung cancer remain unclear. In the present study, it was identified that Lewis lung carcinoma cells actively released the danger-associated molecular pattern protein high mobility group box 1 (HMGB1). Furthermore, HMGB1 in lung cancer cell supernatants promoted the formation of neutrophil extracellular traps (NETs), which was dependent on Toll-like receptor 4 (TLR4). The downstream molecules of TLR4, including myeloid differentiation factor 88, TIR-domain-containing adapter-inducing interferon-β, p38 mitogen-activated protein kinases (p38 MAPKs) and extracellular signal-regulated kinases (ERKs), were activated during the formation of NETs. In addition, inhibition of p38 MAPKs or ERKs significantly decreased NETs. Morphine, an additional ligand for TLR4, aggravated the NETs induced by lung cancer cells. The present study revealed novel mechanisms in tumor-associated NET formation.

Introduction

Lung cancer is one of the most devastating diseases worldwide. Neutrophil infiltration is frequently observed in lung cancer tissues (1). Neutrophil extracellular traps (NETs), composed of extracellular DNA, hypercitrullined histones and antimicrobial enzymes from neutrophils, may increase the adhesion of cancer cells (2) and sequester lung cancer cells in the blood (3). NET formation has previously been described in patients with lung cancer (4). However, the mechanisms regulating the formation of NETs associated with lung cancer are yet to be fully elucidated.

Diverse stimuli have been suggested to initiate the formation of NETs, ranging from pathogen components (5) to neutrophil antibodies (6) and activated platelets (7). In addition, interleukin (IL)-1β (8), IL-8 (9) or granulocyte colony stimulating factor (G-CSF) (10) in the tumor microenvironment may also promote NET formation. As a damage-associated molecular pattern protein, high mobility group box 1 (HMGB1) serves a paradoxical role in regulating cell death and survival in tumor development (11). HMGB1 interactions with Toll-like receptor 4 (TLR4) have been demonstrated to induce NET formation. As a damage-associated molecular pattern protein, high mobility group box 1 (HMGB1) serves a paradoxical role in regulating cell death and survival in tumor development (11). HMGB1 interactions with Toll-like receptor 4 (TLR4) have been demonstrated to induce NETs (12). Therefore, it was hypothesized that lung cancer cells may release HMGB1, which may induce NET formation.

Morphine is an effective analgesic for cancer-associated pain. In the end-stages of lung cancer, continuous morphine infusion is used to alleviate pain (13). Although pain adversely affects the prognosis of patients with lung cancer, morphine administration controls the pain but does not improve survival (14). Arguably, morphine may stimulate angiogenesis and promote tumor progression (15,16). HMGB1 and morphine are able to bind with TLR4 (17,18). The present study aimed to evaluate the role of HMGB1 from lung cancer cells in the formation of NETs. In addition, the effect of morphine on HMGB1-induced NETs was investigated.

Materials and methods

Animals and ethics statement. In total, 40 wild-type female ICR mice (age matched 8-10 weeks old) weighing 29-32 g were purchased from Yangzhou University (Yangzhou, China) and bred in the animal facility of Nanjing Medical University (Nanjing, China) under standard laboratory conditions (12:12 h light:dark cycle, relative humidity 60±5%, temperature 25±2°C) in individually ventilated cages without restriction to water or food. All animal procedures were approved by The
Institutional Animal Care Committee of Nanjing Medical University.

Lewis lung carcinoma (LLC) cell culture and flow cytometry. The murine LLC cell line was purchased from the Cell Bank of the Shanghai Institute for Biological Sciences, Chinese Academy of Sciences. LLC cells were maintained in high-glucose Dulbecco’s modified Eagle’s medium (HyClone; GE Healthcare Life Sciences) supplemented with penicillin (100 U/ml), streptomycin (100 µg/ml) and 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) in a 5% CO₂ humidified atmosphere at 37°C.

Cells which had adhered to the base of the T-25 flask were dislodged by aspiration several times with culture medium. The supernatants were used to stimulate neutrophils for NETs as described subsequently. The LLC cells were resuspended in PBS buffer with 1% BSA (Sigma-Aldrich; Merck KGaA). Aliquots containing 1x10⁶ cells in 100 µl buffer were stained with 10-µl propidium iodide (50 mg/ml) solution and with 5 µl LLC cell supernatants for 4 h.

Concomitantly, prior to stimulation with LLC cell supernatants or positive control, neutrophils were pretreated with morphine (10 nM; Sigma-Aldrich; Merck KGaA) or naloxone (100 nM; Sigma-Aldrich; Merck KGaA) or with 100 µM ketamine hydrochloride (Rogar/STB; Pfizer Canada, Inc.) prior to sacrifice by cervical dislocation. Following sacrifice, the femur and the tibia from the two hind legs were removed and the extreme distal tip of each extremity was cut off. PBS solution was forced through the bone with a 1 ml syringe. Following ammonium chloride erythrocyte lysis, murine neutrophils were prepared by Histopaque-based density gradient centrifugation, as described previously (19).

Quantification of NETs released from neutrophils. Terminal anesthesia was performed by intraperitoneal injection of a mixture of 10 mg/kg xylazine (MTC Pharmaceuticals) and 100 mg/kg ketamine hydrochloride (Rogar/STB; Pfizer Canada, Inc.) prior to sacrifice by cervical dislocation. Following sacrifice, the femur and the tibia from the two hind legs were removed and the extreme distal tip of each extremity was cut off. PBS solution was forced through the bone with a 1 ml syringe. Following ammonium chloride erythrocyte lysis, murine neutrophils were prepared by Histopaque-based density gradient centrifugation, as described previously (19).

Murine neutrophils were unstimulated or challenged with LLC cell supernatants for 2.4 or 8 h. Following incubation, the non-cell-permeable DNA dye Sytox Green (5 µM; Invitrogen; Thermo Fisher Scientific, Inc.) was used to quantify the released NETs in the supernatants as described previously (20). The samples were examined with a fluorometric reader Infiniti M200 (Tecan Group, Ltd.) using an excitation wavelength of 488 nm and an emission wavelength of 523 nm, as described subsequently. The LLC cells were resuspended in PBS buffer with 1% BSA (Sigma-Aldrich; Merck KGaA). Aliquots containing 1x10⁶ cells in 100 µl buffer were stained with 10-µl propidium iodide (50 mg/ml) solution and with 5 µl LLC cell supernatants for 4 h.

Following incubation, neutrophils were fixed with ice-cold acetone (≥99%) for 10 min at room temperature. The samples were blocked with 5% goat serum (cat. no. 16210072, Gibco, Thermo Fisher Scientific, Inc.) and probed with the following antibodies at 1:1,000 dilution overnight at 4°C: Anti-Histone H3 (cat. no. 4499s; Cell Signaling Technology, Inc.), anti-histone3 (cat. no. ab5103; citrulline R2+R8+R17; Abcam), MAPK/Phospho-MAPK family antibody (cat. no. 9926; Cell Signaling Technology, Inc.), anti-TIR-domain-containing adapter-inducing interferon-β (TRIF) antibody (cat. no. ab3810, Abcam), anti-HMGBl antibody (cat. no. 10829-1-AP, ProteinTech Group, Inc., Chicago, IL, USA) and anti-myeloid differentiation factor 88 (MyD88) antibody (cat. no. 4283; Cell Signaling Technology, Inc.). This was followed by incubation with horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (dilution 1:10,000; cat. no. ab6721; Abcam) in PBS with 0.5% BSA for 1 h at room temperature. Signals were developed and analyzed using the chemiluminescent horseradish peroxidase substrate (EMD Millipore) and the G:BOX system (Syngene Europe). Grayscale analysis was performed using Adobe Photoshop CS6 (v13.0 x32; Adobe Systems Europe, Ltd., Maidenhead, UK).

Immunofluorescence microscopy. Neutrophils (1x10⁶) were seeded on glass-bottomed dishes (Shanghai Jing An biological science and Technology Co., Ltd.). According to the aforementioned method, LLC cell supernatants or different inhibitors were added. Following 4 h of incubation, cells that adhered to the bottom of the glass were carefully fixed with ice-cold acetone (≥99%) for 10 min at room temperature. The samples were blocked with 5% goat serum (cat. no. 16210072, Gibco, Thermo Fisher Scientific, Inc.) and stained overnight at 4°C with rabbit polyclonal antibody against Histone3 (cat. no. ab5103, citrulline R2+R8+R17; 1:300; Abcam). The samples were washed in PBST and stained with Alexa Fluor® 555 goat anti-rabbit antibody (1:500; cat. no. A-21428; Thermo Fisher Scientific, Inc.). DNA in the samples was stained with Sytox Green (Invitrogen; Thermo Fisher Scientific, Inc.; 1:10,000) for 30 min at room temperature. Images were captured using Carl Zeiss confocal microscopes (Carl Zeiss AG) with appropriate lenses and filters (magnification, 200x).

Statistical analysis. Statistical analysis was performed using GraphPad Prism 5 (GraphPad Software, Inc.). Data are presented as the mean ± standard error of the mean. One-way analysis of variance and a post-hoc Tukey’s honest significant difference test was used to compare multiple groups. P<0.05 was considered to indicate a statistically significant difference.
Results

HMGB1 from LLC cells induces NETs. In the complete culture medium from LLC cells, HGMB1 was detected (Fig. 1A). As expected, in the complete medium, only a small number of tumor cells underwent apoptosis or necrosis (Fig. 1B). Therefore, it was determined that LLC cells actively released HGMB1 without exogenous stimulus.
As recombinant HMGB1 is able to induce NETs (12), it was hypothesized that LLC cell supernatants containing HMGB1 may also trigger the formation of NETs. Neutrophils were treated with LLC cell supernatants and the extracellular DNA (exDNA) was measured using DNA dye Sytox Green. As indicated in Fig. 1C, exDNA was progressively increased, suggesting that upon LLC cell supernatant challenge, neutrophils produced exDNA during the cell culture for 8 h. To verify whether HMGB1 was involved with exDNA production, HMGB1 inhibitor GA was added to the neutrophil culture. GA significantly alleviated the exDNA production evoked by LLC cell supernatant (Fig. 1D), suggesting that the role of LLC cell supernatant in exDNA induction was at least partially dependent on HMGB1.

exDNA may originate from necrotic neutrophils or neutrophils with NETs. However, necrosis may be differentiated from neutrophils with NETs due to the observation of histone hypercitrullination in NETs (21). Therefore, histone hypercitrullination was evaluated in the neutrophils treated with LLC cell supernatant. As indicated in Fig. 1E, hypercitrullinated histone 3 expression was significantly increased in the neutrophils treated with LLC cell supernatant. In addition, HMGB1 inhibitor rescued the deleterious effects of LLC cell supernatant. Under confocal microscopy, LLC cell supernatant-treated neutrophils were observed to produce exDNA overlaid with hypercitrullinated histone 3, which was alleviated by treatment with HMGB1 inhibitor GA (Fig. 1F). These results indicate that lung cancer cells actively release HMGB1, which directly promotes the formation of NETs.

**TLR4 is required for lung cancer cell-induced NETs.** As a damage-associated molecular pattern protein, soluble HMGB1...
may bind with diverse receptors, including TLR4, the receptor for advanced glycation end products, macrophage adhesion molecule-1, receptor-type protein-tyrosine phosphatase-ζ/β, chemokine (C-X-C motif) ligand 4, T-cell immunoglobulin mucin-3, cluster of differentiation 24 and syndecan 1 (11). Among these potential receptors, TLR4 is highly expressed on neutrophils (22) and closely associated with NETs. In bacterial sepsis, platelet TLR4 detected ligands and promoted NETs (7). Furthermore, NETs induced by recombinant HMGB1 were dependent on TLR4 (12). Therefore, in the present study, the role of TLR4 in LLC cell supernatant-induced NETs was explored.
C34 is a selective TLR4 inhibitor (23). ExDNA and histone 3 hypercitrullination were significantly decreased upon C34 treatment (Fig. 2A-C), suggesting that TLR4 may be required in LLC cell-induced NETs. Consistent with the observations of exDNA and histone 3 hypercitrullination, C34 also diminished NET formation as observed by confocal microscopy (Fig. 2D). Although C34 selectively targets TLR4 (23), TLR4 knockout neutrophils may be required to confirm whether LLC cell-induced NETs was via TLR4. Nevertheless, these results indicate that TLR4-HMBG1 may be required for lung cancer cell-induced NETs.

**MAPK pathway is involved in lung cancer cell-induced NETs.** Soluble HMGB1, once bound with TLR4, may trigger signal transduction via MyD88 or TRIF (24). As indicated in Fig. 3A, treatment with LLC cell supernatants resulted in the significant increase of MyD88 and TRIF. Once bound with the cytoplasmic portion of TLR4, Myd88 recruits nuclear factor-κB and MAPK (25), which have been demonstrated to be essential in NET formation (26,27). As indicated in Fig. 3B and C, phosphorylation of p38 MAPKs, ERK or Janus kinase was significantly increased in the neutrophils treated with lung cancer cell supernatants. Furthermore, p38 MAPKs inhibitor sb203580 or ERK inhibitor U0126 significantly decreased the level of NETs induced by lung cancer cell supernatants (Fig. 3D), suggesting that p38 MAPKs and ERK were involved in lung cancer cell-induced NETs. These results indicate that HMGB1 induced NET formation via TLR4 and p38 MAPKs/ERK.

Morphine promotes lung cancer cell-induced NETs. The aforementioned results indicate that HMGB1 released from lung cancer cells induces NETs via the TLR4/MAPK signaling pathway. To alleviate cancer-associated pain, patients with lung cancer may be administered morphine, which also binds with TLR4 (17,18). Therefore, neutrophils infiltrated into lung tissues may be stimulated by HMGB1 and morphine. To explore the combinational effects of morphine and HMGB1...
on NETs, neutrophils were treated with morphine and LLC cell supernatants. In the preliminary experiment, morphine alone did not evoke the formation of NETs (Fig. 4). However, morphine augmented the formation of NETs induced by lung cancer cell supernatants (Fig. 5). Naloxone, an antagonist of morphine, significantly inhibited the effect of morphine on NET induction, suggesting that opioid receptors may also be involved. In summary, these results indicate that morphine may promote lung cancer cell-induced NETs.

Discussion

Increased levels of HMGB1 are associated with increased disease severity in patients with non-small cell lung cancer (28,29). In chemotherapy, HMGB1 passively released from necrotic cancer cells may increase invasion and metastasis. Cancer cells may also actively secrete HMGB1 upon exogenous and endogenous stimuli (11). Although HMGB1-stimulated NETs have been described previously (12), the role of this in cancer remains unclear. The present study provided evidence that HMGB1 from cancer cells may contribute to NET formation.

Once bound with neutrophil TLR4, HMGB1 induces the activation of Myd88 and TRIF. Although neutrophils express TRIF, it has been demonstrated that the TLR4 ligand lipopolysaccharide is not able to mobilize the TRIF signaling pathway, indicating that TRIF may not be directly involved with neutrophil TLR4 activation (30). In ischemia-reperfusion injury, HMGB1-TLR4-mediated acute cerebral infarct was identified to be TRIF-independent (31). Therefore, the present study focused on TLR4-Myd88 signal transduction initiated by HMGB1 in lung cancer cell supernatants. Activated platelets induced NETs in a pathway that involved TLR4 but was independent of p38 MAPKs (32). In inflammatory disease, oxidized low-density lipoprotein triggered the activation of p38 MAPKs/ERK and the formation of NETs through TLR2 and TLR6 (33). TLR2/TLR6 is also able to bind with HMGB1 (34). Therefore, signal transduction in the formation of NETs may vary depending on the stimulus. In the present study, it was demonstrated that HMGB1 from lung cancer cells induced NETs, which was at least partially dependent on the TLR4 and p38 MAPKs/ERK signaling pathway.

As an analgesic for treating severe pain, morphine may suppress the immune response, impairing the function of T cells and macrophages (35). In addition, neutrophils from patients with sepsis are able to release endogenous morphine, which may inhibit inflammation (36). The present study aimed to explore whether morphine contributed to the formation of NETs. In combination with supernatants from lung cancer cells, morphine may aggravate the formation of NETs. In the end-stages of lung cancer, HMGB1 from lung cancer cells and exogenous morphine administration may synergistically fuel the formation of NETs and cancer progression. It would be useful to investigate whether lung cancer cells are able to release endogenous morphine. Future studies will investigate the association between morphine and NETs in greater detail.

In the infiltrated inflammatory cells within the tumor microenvironment, tumor-associated neutrophils confer a poor prognosis (37). In breast cancer, G-CSF-induced NETs facilitate metastasis (38). As HMGB1 from lung cancer cells and morphine have been indicated to promote the formation of NETs, it is postulated that targeting NETs and their initiators, including HMGB1 and morphine, may be valuable in cancer therapy.

The present study contains certain limitations. Firstly, the mechanisms through which lung cancer cells actively release HMGB1 were not explored. Secondly, the effects of NETs in vivo were not assessed. Thirdly, NETs formation in the patients with lung cancer with or without morphine treatment was not compared. However, the observations from the present study clearly indicated that HMGB1 from lung cancer cells and morphine contributed to the NETs formation, which may provide additional information concerning the tumorigenesis of lung cancer.

Acknowledgements

Not applicable.

Funding

The present study was supported by National Natural Science Foundation of China (grant no. 81671563), Natural Science Foundation of Jiangsu Province (grant no. BK2015155) and Nanjing Medical University key project (grant no. 2014NJMUZD010).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

YC and MZ conceived and designed the study. JZ, YY, TG and YL conducted the experiments; FH, NH, BY and MZ analyzed the results. All authors reviewed and approved the manuscript.

Ethics approval and consent to participate

All animal procedures were approved by the Institutional Animal Care Committee of Nanjing Medical University.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Bar-Ad V, Palmer J, Li L, Lai Y, Lu B, Myers RE, Ye Z, Axelrod R, Johnson JM, Werner-Wasik M, et al: Neutrophil to lymphocyte ratio associated with prognosis of lung cancer. Clin Transl Oncol 19: 711-717, 2017.
2. Najmeh S, Cools-Lartigue J, Giannias B, Spicer J and Ferri LE: Simplified human neutrophil extracellular traps (NETs) isolation and handling. J Vis Exp, 2015.
3. Cools-Lartigue J, Spicer J, McDonald B, Gowing S, Chow S, Giannias B, Bourdeau F, Kubes P and Ferri L: Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest: July 1, 2019.

4. Oklu R, Sheth RA, Wong KH, Jahromi AH and Albadawi H: Neutrophil extracellular traps are increased in cancer patients but does not associate with venous thrombosis. Cardiovasc Diagn Ther 7 (Suppl 3): S140-S149, 2017.

5. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y and Zychlinsky A: Neutrophil extracellular traps kill bacteria. Science 303: 1532-1535, 2004.

6. Ben-Smith A, Dove SK, Martin A, Wakelam MJ and Savage CO: Antineutrophil cytoplasm autoantibodies from patients with systemic vasculitis activate neutrophils through distinct signaling cascades: Comparison with conventional Fc gamma receptor ligations. Blood 98: 1448-1455, 2001.

7. Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, Patel KD, Chakrabarti S, McAvoy E, SinclairGD et al: Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 13: 463-469, 2007.

8. Mitroulis I, Kambas K, Chrysanthopoulou A, Skendros P, Apostolidou E, Kourtzelis I, Drosos G, Boumpas DT and Ritis K: Neutrophil extracellular trap formation is associated with IL-1beta and autophagy-related signaling in gut. PLoS ONE 6: e21510, 2011.

9. Gupta AK, Joshi MB, Erne P, Hasler P, Hahn S et al: HMGB1 FROM LUNG CANCER AND PROMOTED NETs This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.

10. Zylla D, Kuskowski MA, Le C, Gupta K and Gupta P: Association of opioid receptor requirement and cancer pain with survival in advanced non-small cell lung cancer. Br J Anaesesth 113 (Suppl 1): i4-13, 2014.

11. Kang R, Zhang Q, Zeh HH JI, Lotze MT and Tang D: HMGB1 in cancer: Good, bad, or both? Clin Cancer Res 19: 4046-4057, 2013.

12. Takeda K and Akira S: TLR signaling pathways. Semin Immunol 16: 3-9, 2004.

13. Kim YH, Okuda C, Sakamori Y, Masago K, Togashi Y and Mishima M: Continuous morphine infusion for end-stage lung cancer patients. Oncol Lett 5: 972-974, 2013.

14. Zylla D, Kuskowski MA, Gupta K and Gupta P: Association of opioid receptor requirement and cancer pain with survival in advanced non-small cell lung cancer. Br J Anaesth 113 (Suppl 1): i4-13, 2014.

15. Nguyen J, Luk K, Vang D, Soto W, Vincent L, Robiner S, Saavedra R, Li Y, Gupta P and Gupta K: Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer. J Immunol 193: 1954-1965, 2014.

16. Behnen M, Leschczyk C, Moller S, Batel T, Klinger M, Solbach W and Laskay T: Immobilized immune complexes induce neutrophil extracellular trap release by human neutrophil granulocytes via Fc gamma RIIB and Mac-1. J Immunol 193: 1954-1965, 2014.

17. Shah M, Anwar MA, Yesudhas D, Krishnan J and Choi S: A structural insight into the negative effects of opioids in analgesia by modulating the TLR4 signaling: An in silico approach. Sci Rep 6: 39271, 2016.

18. Shah M and Choi S: Toll-like Receptor-Dependent Negative Effects of Opioids: A Battle between Analgesia and Hyperalgesia. Front Immunol 8: 642, 2017.

19. Swamydas M, Luo Y, Dorf MJ and Lionakis MS: Isolation of human neutrophil extracellular traps in vitro. J Immunol Methods 337: 21-27, 2009.

20. Behnen M, Leschczyk C, Moller S, Batel T, Klinger M, Solbach W and Laskay T: Immobilized immune complexes induce neutrophil extracellular trap release by human neutrophil granulocytes via Fc gamma RIIB and Mac-1. J Immunol 193: 1954-1965, 2014.

21. Brinkmann V and Zychlinsky A: Neutrophil extracellular traps: Is immunity the second function of chromatin? J Cell Biol 198: 773-783, 2012.

22. Hayashi F, Means TK and Luster AD: Toll-like receptors stimulate human neutrophil function. Blood 102: 2660-2669, 2003.

23. Neal MD, Jia H, Eyer B, Good M, Guerriero CJ, Sodhi CP, Afrazi A, Prindle T Jr, Ma C, Branca M, et al: Discovery and validation of a new class of small molecule Toll-like receptor 4 (TLR4) inhibitors. PLoS One 8: e65779, 2013.

24. Reino DC, Pisarenko V, Palange D, Doucet D, Bonitz RP, Lu Q, Colorado I, Sheth SU, Chandler B, Kannan KB, et al: Trauma hemorrhagic shock-induced lung injury involves a gut-lymph-induced TLR4 pathway in mice. PLoS One 6: e14829, 2011.

25. Takeda K and Akira S: TLR signaling pathways. Semin Immunol 16: 3-9, 2004.

26. Laponni MJ, Carestia A, Landoni VI, Rivadenearya E, Etulain J, Negrotto S, Pozner RG and Schattner M: Regulation of neutrophil extracellular trap formation by anti-inflammatory drugs. J Pharmacol Exp Ther 345: 430-437, 2013.

27. Hakkim A, Fuchs TA, Martinez NE, Hess S, Prinz H, Zychlinsky A and Waldmann H: Activation of the Ral-MEK-ERK pathway is required for neutrophil extracellular trap formation. Nat Chem Biol 7: 75-77, 2011.

28. Niki M, Yokoi T, Kurata T and Nomura S: New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer. Lung Cancer (Auckl) 8: 91-99, 2017.

29. Tamassia N, Le Moigne V, Calzetti F, Donini M, Gasperini S, Ear T, Cloutier A, Martinez FO, Fabbrli M, Locati M, et al: The MyD88-independent pathway is not mobilized in human neutrophils stimulated via TLR4. J Immunol 178: 7344-7356, 2007.

30. Yang QW, Lu FL, Zhou Y, Wang L, Zhong Q, Lin S, Xiang J, Li JC, Fang CQ and Wang JZ: HMGB1 mediates ischemia-reperfusion injury by TRIF-adaptor independent Toll-like receptor 4 signaling. J Cereb Blood Flow Metab 31: 593-603, 2011.

31. Carestia A, Kaufman T, Rivadenearya L, Landoni VI, Pozner RG, Negrotto S, D’Atri LP, Gómez RM and Schattner M: Mediators and molecular pathways involved in the regulation of neutrophil extracellular trap formation mediated by activated platelets. J Leukoc Biol 99: 153-162, 2016.

32. Awasthi D, Nagarkoti S, Kumar A, Dubey M, Singh AK, Pathak P, Chandra T, Barthwal MK and Dikshit M: Oxidized LDL induced extracellular trap formation in human neutrophils via TLR-PKC-IRAK-MAPK and NADPH-oxidase activation. Free Radic Biol Med 93: 190-203, 2016.

33. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Katona MJ, Tracey KJ and Yang H: HMGB1 signals through toll-like receptor (TLR4) and TLR2. Shock 26: 174-179, 2006.

34. Plen LM and Rittner HL: Opioids and the immune system-friend or foe. Br J Pharmacol 175: 2717-2725, 2017.

35. Glattard E, Welters ID, Lavaux T, Muller AH, Laux A, Zhang D, Schmidt AR, Delalande F, Laventie BJ, Dirrig-Grosch S, et al: Endogenous morphine levels are increased in sepsis: A partial implication of neutrophils. PLoS One 5: e8791, 2010.

36. Gregory AD and Houghton AM: Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 71: 2411-2416, 2011.

37. Berger-Achituv S, Brinkmann V, Abed UA, Kuhn LI, Ben-Ezra J, Elhadad S and Zychlinsky A: A proposed role for neutrophil extracellular traps in cancer immunoeediting. Front Immunol 4: 48, 2013.